共查询到20条相似文献,搜索用时 31 毫秒
1.
Mikael K. Schnizler Katrin Schnizler Xiang-ming Zha Duane D. Hall John A. Wemmie Johannes W. Hell Michael J. Welsh 《The Journal of biological chemistry》2009,284(5):2697-2705
The acid-sensing ion channel 1a (ASIC1a) is widely expressed in central and
peripheral neurons where it generates transient cation currents when
extracellular pH falls. ASIC1a confers pH-dependent modulation on postsynaptic
dendritic spines and has critical effects in neurological diseases associated
with a reduced pH. However, knowledge of the proteins that interact with
ASIC1a and influence its function is limited. Here, we show that
α-actinin, which links membrane proteins to the actin cytoskeleton,
associates with ASIC1a in brain and in cultured cells. The interaction
depended on an α-actinin-binding site in the ASIC1a C terminus that was
specific for ASIC1a versus other ASICs and for α-actinin-1 and
-4. Co-expressing α-actinin-4 altered ASIC1a current density, pH
sensitivity, desensitization rate, and recovery from desensitization.
Moreover, reducing α-actinin expression altered acid-activated currents
in hippocampal neurons. These findings suggest that α-actinins may link
ASIC1a to a macromolecular complex in the postsynaptic membrane where it
regulates ASIC1a activity.Acid-sensing ion channels
(ASICs)2 are
H+-gated members of the DEG/ENaC family
(1–3).
Members of this family contain cytosolic N and C termini, two transmembrane
domains, and a large cysteine-rich extracellular domain. ASIC subunits combine
as homo- or heterotrimers to form cation channels that are widely expressed in
the central and peripheral nervous systems
(1–4).
In mammals, four genes encode ASICs, and two subunits, ASIC1 and ASIC2, have
two splice forms, a and b. Central nervous system neurons express ASIC1a,
ASIC2a, and ASIC2b
(5–7).
Homomeric ASIC1a channels are activated when extracellular pH drops below 7.2,
and half-maximal activation occurs at pH 6.5–6.8
(8–10).
These channels desensitize in the continued presence of a low extracellular
pH, and they can conduct Ca2+
(9,
11–13).
ASIC1a is required for acid-evoked currents in central nervous system neurons;
disrupting the gene encoding ASIC1a eliminates H+-gated currents
unless extracellular pH is reduced below pH 5.0
(5,
7).Previous studies found ASIC1a enriched in synaptosomal membrane fractions
and present in dendritic spines, the site of excitatory synapses
(5,
14,
15). Consistent with this
localization, ASIC1a null mice manifested deficits in hippocampal
long term potentiation, learning, and memory, which suggested that ASIC1a is
required for normal synaptic plasticity
(5,
16). ASICs might be activated
during neurotransmission when synaptic vesicles empty their acidic contents
into the synaptic cleft or when neuronal activity lowers extracellular pH
(17–19).
Ion channels, including those at the synapse often interact with multiple
proteins in a macromolecular complex that incorporates regulators of their
function (20,
21). For ASIC1a, only a few
interacting proteins have been identified. Earlier work indicated that ASIC1a
interacts with another postsynaptic scaffolding protein, PICK1
(15,
22,
23). ASIC1a also has been
reported to interact with annexin II light chain p11 through its cytosolic N
terminus to increase cell surface expression
(24) and with
Ca2+/calmodulin-dependent protein kinase II to phosphorylate the
channel (25). However, whether
ASIC1a interacts with additional proteins and with the cytoskeleton remain
unknown. Moreover, it is not known whether such interactions alter ASIC1a
function.In analyzing the ASIC1a amino acid sequence, we identified cytosolic
residues that might bind α-actinins. α-Actinins cluster membrane
proteins and signaling molecules into macromolecular complexes and link
membrane proteins to the actincytoskeleton (for review, Ref.
26). Four genes encode
α-actinin-1, -2, -3, and -4 isoforms. α-Actinins contain an
N-terminal head domain that binds F-actin, a C-terminal region containing two
EF-hand motifs, and a central rod domain containing four spectrin-like motifs
(26–28).
The C-terminal portion of the rod segment appears to be crucial for binding to
membrane proteins. The α-actinins assemble into antiparallel homodimers
through interactions in their rod domain. α-Actinins-1, -2, and -4 are
enriched in dendritic spines, concentrating at the postsynaptic membrane
(29–35).
In the postsynaptic membrane of excitatory synapses, α-actinin connects
the NMDA receptor to the actin cytoskeleton, and this interaction is key for
Ca2+-dependent inhibition of NMDA receptors
(36–38).
α-Actinins can also regulate the membrane trafficking and function of
several cation channels, including L-type Ca2+ channels,
K+ channels, and TRP channels
(39–41).To better understand the function of ASIC1a channels in macromolecular
complexes, we asked if ASIC1a associates with α-actinins. We were
interested in the α-actinins because they and ASIC1a, both, are present
in dendritic spines, ASIC1a contains a potential α-actinin binding
sequence, and the related epithelial Na+ channel (ENaC) interacts
with the cytoskeleton (42,
43). Therefore, we
hypothesized that α-actinin interacts structurally and functionally with
ASIC1a. 相似文献
2.
3.
Yun Liu Yun-wu Zhang Xin Wang Han Zhang Xiaoqing You Francesca-Fang Liao Huaxi Xu 《The Journal of biological chemistry》2009,284(18):12145-12152
Excessive accumulation of β-amyloid peptides in the brain is a major
cause for the pathogenesis of Alzheimer disease. β-Amyloid is derived
from β-amyloid precursor protein (APP) through sequential cleavages by
β- and γ-secretases, whose enzymatic activities are tightly
controlled by subcellular localization. Delineation of how intracellular
trafficking of these secretases and APP is regulated is important for
understanding Alzheimer disease pathogenesis. Although APP trafficking is
regulated by multiple factors including presenilin 1 (PS1), a major component
of the γ-secretase complex, and phospholipase D1 (PLD1), a
phospholipid-modifying enzyme, regulation of intracellular trafficking of
PS1/γ-secretase and β-secretase is less clear. Here we demonstrate
that APP can reciprocally regulate PS1 trafficking; APP deficiency results in
faster transport of PS1 from the trans-Golgi network to the cell
surface and increased steady state levels of PS1 at the cell surface, which
can be reversed by restoring APP levels. Restoration of APP in APP-deficient
cells also reduces steady state levels of other γ-secretase components
(nicastrin, APH-1, and PEN-2) and the cleavage of Notch by
PS1/γ-secretase that is more highly correlated with cell surface levels
of PS1 than with APP overexpression levels, supporting the notion that Notch
is mainly cleaved at the cell surface. In contrast, intracellular trafficking
of β-secretase (BACE1) is not regulated by APP. Moreover, we find that
PLD1 also regulates PS1 trafficking and that PLD1 overexpression promotes cell
surface accumulation of PS1 in an APP-independent manner. Our results clearly
elucidate a physiological function of APP in regulating protein trafficking
and suggest that intracellular trafficking of PS1/γ-secretase is
regulated by multiple factors, including APP and PLD1.An important pathological hallmark of Alzheimer disease
(AD)4 is the formation
of senile plaques in the brains of patients. The major components of those
plaques are β-amyloid peptides (Aβ), whose accumulation triggers a
cascade of neurodegenerative steps ending in formation of senile plaques and
intraneuronal fibrillary tangles with subsequent neuronal loss in susceptible
brain regions (1,
2). Aβ is proteolytically
derived from the β-amyloid precursor protein (APP) through sequential
cleavages by β-secretase (BACE1), a novel membrane-bound aspartyl
protease (3,
4), and by γ-secretase, a
high molecular weight complex consisting of at least four components:
presenilin (PS), nicastrin (NCT), anterior pharynx-defective-1 (APH-1), and
presenilin enhancer-2 (PEN-2)
(5,
6). APP is a type I
transmembrane protein belonging to a protein family that includes APP-like
protein 1 (APLP1) and 2 (APLP2) in mammals
(7,
8). Full-length APP is
synthesized in the endoplasmic reticulum (ER) and transported through the
Golgi apparatus. Most secreted Aβ peptides are generated within the
trans-Golgi network (TGN), also the major site of steady state APP in
neurons
(9–11).
APP can be transported to the cell surface in TGN-derived secretory vesicles
if not proteolyzed to Aβ or an intermediate metabolite. At the cell
surface APP is either cleaved by α-secretase to produce soluble
sAPPα (12) or
reinternalized for endosomal/lysosomal degradation
(13,
14). Aβ may also be
generated in endosomal/lysosomal compartments
(15,
16). In contrast to neurotoxic
Aβ peptides, sAPPα possesses neuroprotective potential
(17,
18). Thus, the subcellular
distribution of APP and proteases that process it directly affect the ratio of
sAPPα to Aβ, making delineation of the mechanisms responsible for
regulating trafficking of all of these proteins relevant to AD
pathogenesis.Presenilin (PS) is a critical component of the γ-secretase. Of the
two mammalian PS gene homologues, PS1 and PS2, PS1
encodes the major form (PS1) in active γ-secretase
(19,
20). Nascent PSs undergo
endoproteolytic cleavage to generate an amino-terminal fragment (NTF) and a
carboxyl-terminal fragment (CTF) to form a functional PS heterodimer
(21). Based on observations
that PSs possess two highly conserved aspartate residues indispensable for
γ-secretase activity and that specific transition state analogue
γ-secretase inhibitors bind to PS1 NTF/CTF heterodimers
(5,
22), PSs are believed to be
the catalytic component of the γ-secretase complex. PS assembles with
three other components, NCT, APH-1, and PEN-2, to form the functional
γ-secretase (5,
6). Strong evidence suggests
that PS1/γ-secretase resides principally in the ER, early Golgi, TGN,
endocytic and intermediate compartments, most of which (except the TGN) are
not major subcellular sites for APP
(23,
24). In addition to generating
Aβ and cleaving APP to release the APP intracellular domain,
PS1/γ-secretase cleaves other substrates such as Notch
(25), cadherin
(26), ErbB4
(27), and CD44
(28), releasing their
respective intracellular domains. Interestingly, PS1/γ-secretase
cleavage of different substrates seems to occur at different subcellular
compartments; APP is mainly cleaved at the TGN and early endosome domains,
whereas Notch is predominantly cleaved at the cell surface
(9,
11,
29). Thus, perturbing
intracellular trafficking of PS1/γ-secretase may alter interactions
between PS1/γ-secretase and APP, contributing to either abnormal Aβ
generation and AD pathogenesis or decreased access of PS1/γ-secretase to
APP such that Aβ production is reduced. However, mechanisms regulating
PS1/γ-secretase trafficking warrant further investigation.In addition to participating in γ-secretase activity, PS1 regulates
intracellular trafficking of several membrane proteins, including other
γ-secretase components (nicastrin, APH-1, and PEN-2) and the substrate
APP (reviewed in Ref. 30).
Intracellular APP trafficking is highly regulated and requires other factors
such as mint family members and SorLA
(2). Moreover, we recently
found that phospholipase D1 (PLD1), a phospholipid-modifying enzyme that
regulates membrane trafficking events, can interact with PS1, and can regulate
budding of APP-containing vesicles from the TGN and delivery of APP to the
cell surface (31,
32). Interestingly, Kamal
et al. (33)
identified an axonal membrane compartment that contains APP, BACE1, and PS1
and showed that fast anterograde axonal transport of this compartment is
mediated by APP and kinesin-I, implying a traffic-regulating role for APP.
Increased APP expression is also shown to decrease retrograde axonal transport
of nerve growth factor (34).
However, whether APP indeed regulates intracellular trafficking of proteins
including BACE1 and PS1/γ-secretase requires further validation. In the
present study we demonstrate that intracellular trafficking of PS1, as well as
that of other γ-secretase components, but not BACE1, is regulated by
APP. APP deficiency promotes cell surface delivery of PS1/γ-secretase
complex and facilitates PS1/γ-secretase-mediated Notch cleavage. In
addition, we find that PLD1 also regulates intracellular trafficking of PS1
through a different mechanism and more potently than APP. 相似文献
4.
Benjamin E. L. Lauffer Stanford Chen Cristina Melero Tanja Kortemme Mark von Zastrow Gabriel A. Vargas 《The Journal of biological chemistry》2009,284(4):2448-2458
Many G protein-coupled receptors (GPCRs) recycle after agonist-induced
endocytosis by a sequence-dependent mechanism, which is distinct from default
membrane flow and remains poorly understood. Efficient recycling of the
β2-adrenergic receptor (β2AR) requires a C-terminal PDZ
(PSD-95/Discs Large/ZO-1) protein-binding determinant (PDZbd), an intact actin
cytoskeleton, and is regulated by the endosomal protein Hrs (hepatocyte growth
factor-regulated substrate). The PDZbd is thought to link receptors to actin
through a series of protein interaction modules present in NHERF/EBP50
(Na+/H+ exchanger 3 regulatory factor/ezrin-binding phosphoprotein
of 50 kDa) family and ERM (ezrin/radixin/moesin) family proteins. It is not
known, however, if such actin connectivity is sufficient to recapitulate the
natural features of sequence-dependent recycling. We addressed this question
using a receptor fusion approach based on the sufficiency of the PDZbd to
promote recycling when fused to a distinct GPCR, the δ-opioid receptor,
which normally recycles inefficiently in HEK293 cells. Modular domains
mediating actin connectivity promoted receptor recycling with similarly high
efficiency as the PDZbd itself, and recycling promoted by all of the domains
was actin-dependent. Regulation of receptor recycling by Hrs, however, was
conferred only by the PDZbd and not by downstream interaction modules. These
results suggest that actin connectivity is sufficient to mimic the core
recycling activity of a GPCR-linked PDZbd but not its cellular regulation.G protein-coupled receptors
(GPCRs)2 comprise the
largest family of transmembrane signaling receptors expressed in animals and
transduce a wide variety of physiological and pharmacological information.
While these receptors share a common 7-transmembrane-spanning topology,
structural differences between individual GPCR family members confer diverse
functional and regulatory properties
(1-4).
A fundamental mechanism of GPCR regulation involves agonist-induced
endocytosis of receptors via clathrin-coated pits
(4). Regulated endocytosis can
have multiple functional consequences, which are determined in part by the
specificity with which internalized receptors traffic via divergent downstream
membrane pathways
(5-7).Trafficking of internalized GPCRs to lysosomes, a major pathway traversed
by the δ-opioid receptor (δOR), contributes to proteolytic
down-regulation of receptor number and produces a prolonged attenuation of
subsequent cellular responsiveness to agonist
(8,
9). Trafficking of internalized
GPCRs via a rapid recycling pathway, a major route traversed by the
β2-adrenergic receptor (β2AR), restores the complement of functional
receptors present on the cell surface and promotes rapid recovery of cellular
signaling responsiveness (6,
10,
11). When co-expressed in the
same cells, the δOR and β2AR are efficiently sorted between these
divergent downstream membrane pathways, highlighting the occurrence of
specific molecular sorting of GPCRs after endocytosis
(12).Recycling of various integral membrane proteins can occur by default,
essentially by bulk membrane flow in the absence of lysosomal sorting
determinants (13). There is
increasing evidence that various GPCRs, such as the β2AR, require
distinct cytoplasmic determinants to recycle efficiently
(14). In addition to requiring
a cytoplasmic sorting determinant, sequence-dependent recycling of the
β2AR differs from default recycling in its dependence on an intact actin
cytoskeleton and its regulation by the conserved endosomal sorting protein Hrs
(hepatocyte growth factor receptor substrate)
(11,
14). Compared with the present
knowledge regarding protein complexes that mediate sorting of GPCRs to
lysosomes (15,
16), however, relatively
little is known about the biochemical basis of sequence-directed recycling or
its regulation.The β2AR-derived recycling sequence conforms to a canonical PDZ
(PSD-95/Discs Large/ZO-1) protein-binding determinant (henceforth called
PDZbd), and PDZ-mediated protein association(s) with this sequence appear to
be primarily responsible for its endocytic sorting activity
(17-20).
Fusion of this sequence to the cytoplasmic tail of the δOR effectively
re-routes endocytic trafficking of engineered receptors from lysosomal to
recycling pathways, establishing the sufficiency of the PDZbd to function as a
transplantable sorting determinant
(18). The β2AR-derived
PDZbd binds with relatively high specificity to the NHERF/EBP50 family of PDZ
proteins (21,
22). A well-established
biochemical function of NHERF/EBP50 family proteins is to associate integral
membrane proteins with actin-associated cytoskeletal elements. This is
achieved through a series of protein-interaction modules linking NHERF/EBP50
family proteins to ERM (ezrin-radixin-moesin) family proteins and, in turn, to
actin filaments
(23-26).
Such indirect actin connectivity is known to mediate other effects on plasma
membrane organization and function
(23), however, and NHERF/EBP50
family proteins can bind to additional proteins potentially important for
endocytic trafficking of receptors
(23,
25). Thus it remains unclear
if actin connectivity is itself sufficient to promote sequence-directed
recycling of GPCRs and, if so, if such connectivity recapitulates the normal
cellular regulation of sequence-dependent recycling. In the present study, we
took advantage of the modular nature of protein connectivity proposed to
mediate β2AR recycling
(24,
26), and extended the opioid
receptor fusion strategy used successfully for identifying diverse recycling
sequences in GPCRs
(27-29),
to address these fundamental questions.Here we show that the recycling activity of the β2AR-derived PDZbd can
be effectively bypassed by linking receptors to ERM family proteins in the
absence of the PDZbd itself. Further, we establish that the protein
connectivity network can be further simplified by fusing receptors to an
interaction module that binds directly to actin filaments. We found that
bypassing the PDZ-mediated interaction using either domain is sufficient to
mimic the ability of the PDZbd to promote efficient, actin-dependent recycling
of receptors. Hrs-dependent regulation, however, which is characteristic of
sequence-dependent recycling of wild-type receptors, was recapitulated only by
the fused PDZbd and not by the proposed downstream interaction modules. These
results support a relatively simple architecture of protein connectivity that
is sufficient to mimic the core recycling activity of the β2AR-derived
PDZbd, but not its characteristic cellular regulation. Given that an
increasing number of GPCRs have been shown to bind PDZ proteins that typically
link directly or indirectly to cytoskeletal elements
(17,
27,
30-32),
the present results also suggest that actin connectivity may represent a
common biochemical principle underlying sequence-dependent recycling of
various GPCRs. 相似文献
5.
6.
Kelvin B. Luther Hermann Schindelin Robert S. Haltiwanger 《The Journal of biological chemistry》2009,284(5):3294-3305
The Notch receptor is critical for proper development where it orchestrates
numerous cell fate decisions. The Fringe family of
β1,3-N-acetylglucosaminyltransferases are regulators of this
pathway. Fringe enzymes add N-acetylglucosamine to O-linked
fucose on the epidermal growth factor repeats of Notch. Here we have analyzed
the reaction catalyzed by Lunatic Fringe (Lfng) in detail. A mutagenesis
strategy for Lfng was guided by a multiple sequence alignment of Fringe
proteins and solutions from docking an epidermal growth factor-like
O-fucose acceptor substrate onto a homology model of Lfng. We
targeted three main areas as follows: residues that could help resolve where
the fucose binds, residues in two conserved loops not observed in the
published structure of Manic Fringe, and residues predicted to be involved in
UDP-N-acetylglucosamine (UDP-GlcNAc) donor specificity. We utilized a
kinetic analysis of mutant enzyme activity toward the small molecule acceptor
substrate 4-nitrophenyl-α-l-fucopyranoside to judge their
effect on Lfng activity. Our results support the positioning of
O-fucose in a specific orientation to the catalytic residue. We also
found evidence that one loop closes off the active site coincident with, or
subsequent to, substrate binding. We propose a mechanism whereby the ordering
of this short loop may alter the conformation of the catalytic aspartate.
Finally, we identify several residues near the UDP-GlcNAc-binding site, which
are specifically permissive toward UDP-GlcNAc utilization.Defects in Notch signaling have been implicated in numerous human diseases,
including multiple sclerosis
(1), several forms of cancer
(2-4),
cerebral autosomal dominant arteriopathy with sub-cortical infarcts and
leukoencephalopathy (5), and
spondylocostal dysostosis
(SCD)3
(6-8).
The transmembrane Notch signaling receptor is activated by members of the DSL
(Delta, Serrate, Lag2) family of ligands
(9,
10). In the endoplasmic
reticulum, O-linked fucose glycans are added to the epidermal growth
factor-like (EGF) repeats of the Notch extracellular domain by protein
O-fucosyltransferase 1
(11-13).
These O-fucose monosaccharides can be elongated in the Golgi
apparatus by three highly conserved
β1,3-N-acetylglucosaminyltransferases of the Fringe family
(Lunatic (Lfng), Manic (Mfng), and Radical Fringe (Rfng) in mammals)
(14-16).
The formation of this GlcNAc-β1,3-Fuc-α1,
O-serine/threonine disaccharide is necessary and sufficient for
subsequent elongation to a tetrasaccharide
(15,
19), although elongation past
the disaccharide in Drosophila is not yet clear
(20,
21). Elongation of
O-fucose by Fringe is known to potentiate Notch signaling from Delta
ligands and inhibit signaling from Serrate ligands
(22). Delta ligands are termed
Delta-like (Delta-like1, -2, and -4) in mammals, and the homologs of Serrate
are known as Jagged (Jagged1 and -2) in mammals. The effects of Fringe on
Drosophila Notch can be recapitulated in Notch ligand in
vitro binding assays using purified components, suggesting that the
elongation of O-fucose by Fringe alters the binding of Notch to its
ligands (21). Although Fringe
also appears to alter Notch-ligand interactions in mammals, the effects of
elongation of the glycan past the O-fucose monosaccharide is more
complicated and appears to be cell type-, receptor-, and ligand-dependent (for
a recent review see Ref.
23).The Fringe enzymes catalyze the transfer of GlcNAc from the donor substrate
UDP-α-GlcNAc to the acceptor fucose, forming the GlcNAc-β1,3-Fuc
disaccharide
(14-16).
They belong to the GT-A-fold of inverting glycosyltransferases, which includes
N-acetylglucosaminyltransferase I and β1,4-galactosyltransferase
I (17,
18). The mechanism is presumed
to proceed through the abstraction of a proton from the acceptor substrate by
a catalytic base (Asp or Glu) in the active site. This creates a nucleophile
that attacks the anomeric carbon of the nucleotide-sugar donor, inverting its
configuration from α (on the nucleotide sugar) to β (in the
product) (24,
25). The enzyme then releases
the acceptor substrate modified with a disaccharide and UDP. The Mfng
structure (26) leaves little
doubt as to the identity of the catalytic residue, which in all likelihood is
aspartate 289 in mouse Lfng (we will use numbering for mouse Lunatic Fringe
throughout, unless otherwise stated). The structure of Mfng with UDP-GlcNAc
soaked into the crystals (26)
showed density only for the UDP portion of the nucleotide-sugar donor and no
density for two loops flanking either side of the active site. The presence of
flexible loops that become ordered upon substrate binding is a common
observation with glycosyltransferases in the GT-A fold family
(18,
25). Density for the entire
donor was observed in the structure of rabbit
N-acetylglucosaminyltransferase I
(27). In this case, ordering
of a previously disordered loop upon UDP-GlcNAc binding may have contributed
to increased stability of the donor. In the case of bovine
β1,4-galactosyltransferase I, a section of flexible random coil from the
apo-structure was observed to change its conformation to α-helical upon
donor substrate binding (28).
Both loops in Lfng are highly conserved, and we have mutated a number of
residues in each to test the hypothesis that they interact with the
substrates. The mutagenesis strategy was also guided by docking of an
EGF-O-fucose acceptor substrate into the active site of the Lfng
model as well as comparison of the Lfng model with a homology model of the
β1,3-glucosyltransferase (β3GlcT) that modifies O-fucose on
thrombospondin type 1 repeats
(29,
30). The β3GlcT is
predicted to be a GT-A fold enzyme related to the Fringe family
(17,
18,
29). 相似文献
7.
Sharareh Emadi Srinath Kasturirangan Min S. Wang Philip Schulz Michael R. Sierks 《The Journal of biological chemistry》2009,284(17):11048-11058
Neuropathologic and genetics studies as well as transgenic animal models
have provided strong evidence linking misfolding and aggregation of
α-synuclein to the progression of Parkinson disease (PD) and other
related disorders. A growing body of evidence implicates various oligomeric
forms of α-synuclein as the toxic species responsible for
neurodegeneration and neuronal cell death. Although numerous different
oligomeric forms of α-synuclein have been identified in vitro,
it is not known which forms are involved in PD or how, when, and where
different forms contribute to the progression of PD. Reagents that can
interact with specific aggregate forms of α-synuclein would be very
useful not only as tools to study how different aggregate forms affect cell
function, but also as potential diagnostic and therapeutic agents for PD. Here
we show that a single chain antibody fragment (syn-10H scFv) isolated from a
phage display antibody library binds to a larger, later stage oligomeric form
of α-synuclein than a previously reported oligomeric specific scFv
isolated in our laboratory. The scFv described here inhibits aggregation of
α-synuclein in vitro, blocks extracellular
α-synuclein-induced toxicity in both undifferentiated and differentiated
human neuroblastoma cell lines (SH-SY5Y), and specifically recognizes
naturally occurring aggregates in PD but not in healthy human brain
tissue.Parkinson disease
(PD)2 is the second
most common neurodegenerative disorder of the elderly, affecting more than
500,000 people in the United States
(1), with 50,000 new cases
reported each year at an annual cost estimated at 10 billion dollars per year.
Pathologically, PD is characterized by the progressive loss of dopaminergic
neurons in the substantia nigra and formation of fibrillar cytoplasmic
inclusions known as Lewy bodies and Lewy neurites
(2,
3). The protein
α-synuclein has been strongly linked to PD
(4,
5) and other related
neurodegenerative disorders (6,
7) by several lines of
evidence. 1) It is the major component of the hallmark Lewy body aggregates
associated with PD. 2) Mutations (A53T, A30P, and E46K, where A30P is human
A30P α-synuclein; A53T is human A53T α-synuclein; E46K is human
E46K α-synuclein) or multiplication in the α-synuclein gene have
been linked to familial PD
(8–10).
3) Overexpression of α-synuclein in transgenic mice and
Drosophila has been shown to induce the formation of PD-like
pathological phenotypes and behavior, although the animal models do not in
general replicate neuronal loss patterns
(11,
12).α-Synuclein is a small protein (14 kDa) expressed mainly in brain
tissues and is primarily localized at the presynaptic terminals of neurons
(13). The primary structure of
α-synuclein consists of three distinct regions. The N-terminal region of
α-synuclein includes the mutation sites associated with familial PD
(A53T, A30P, and E46K) and contains six imperfectly conserved repeats (KTKEGV)
that may facilitate protein-protein binding. This repeat section is predicted
to form amphipathic α-helices, typical of the lipid-binding domain of
apolipoproteins (14). The
central region, non-amyloid component, is extremely hydrophobic and includes a
12-residue stretch (VTGVTAVAQKTV) that is essential for aggregation
(15). The C-terminal region is
enriched with acidic glutamate and aspartate residues and is responsible for
the chaperone function of α-synuclein
(16).α-Synuclein normally exists as an unfolded protein, but it can adopt
several different folded conformations depending on the environment, including
small aggregates or oligomers, spherical and linear protofibrils, as well as
the fibrillar structure found in Lewy bodies
(14,
15). A growing body of
evidence implicates the oligomeric forms of α-synuclein as the toxic
species responsible for neurodegeneration and neuronal cell death
(16–18).
Several different oligomeric forms of α-synuclein including spherical,
annular (19), pore-like
(20), and dopamine-stabilized
structures have been identified in vitro
(21).α-Synuclein is considered a cytosolic protein, and consequently its
pathogenic effect was assumed to be limited to the cytoplasm of single cells.
However, recent studies have suggested that α-synuclein also has
extracellular pathogenic effects
(22–25).
α-Synuclein was detected in blood plasma and cerebrospinal fluid in both
monomeric and oligomeric forms
(22–25),
and the presence of significantly elevated levels of oligomeric species of
α-synuclein has been reported extracellularly in plasma and
cerebrospinal fluid samples from patients with PD
(23). Furthermore, various
studies have shown that aggregated α-synuclein added extracellularly to
the culture medium is cytotoxic
(26–32).Despite all these studies, it is still not clear how the various aggregate
forms of α-synuclein are involved in the progression of PD. Therefore,
reagents that can interact with specific aggregate forms of α-synuclein
would be very useful not only for fundamental studies of how α-synuclein
aggregates affect cell function but also as potential diagnostic and
therapeutic agents for PD.Recently, we reported inhibition of both aggregation and extracellular
toxicity of α-synuclein in vitro by a single chain variable
domain antibody fragment (scFv) that specifically recognized an oligomeric
form of α-synuclein
(32). In this study, we
describe a second scFv (syn-10H) that binds a larger later stage oligomeric
form of α-synuclein than the previously reported scFv. The syn-10H scFv
neutralizes α-synuclein-induced toxicity in both undifferentiated and
differentiated SH-SY5Y human neuroblastoma cell line and inhibits
α-synuclein aggregation in vitro. The syn-10H scFv reacts
specifically with homogenized PD brain tissue but does not cross-react with
similarly treated samples taken from Alzheimer disease (AD) or healthy brain
samples. Such scFvs therefore have potential value as diagnostic reagents to
identify the presence of specific oligomeric species in PD tissue and fluid
samples. The scFvs also have value as therapeutic agents as they can be used
either extracellularly or expressed intracellularly (intrabodies) to prevent
formation of toxic aggregates in vivo whether inside or outside of
cells. Intrabodies have been used efficiently to neutralize toxic effects of
different pathogenic agents, including α-synuclein
(33–36).
Moreover, immunization studies in mouse models of PD have shown that
extracellular antibodies can reduce accumulation of intracellular aggregates
of α-synuclein (37),
thereby providing precedent for the use of scFvs in potential passive
vaccination strategies for treating PD. 相似文献
8.
The inhalation anesthetic desflurane induces caspase activation and increases amyloid beta-protein levels under hypoxic conditions 总被引:1,自引:0,他引:1
Zhang B Dong Y Zhang G Moir RD Xia W Yue Y Tian M Culley DJ Crosby G Tanzi RE Xie Z 《The Journal of biological chemistry》2008,283(18):11866-11875
Perioperative factors including hypoxia, hypocapnia, and certain
anesthetics have been suggested to contribute to Alzheimer disease (AD)
neuropathogenesis. Desflurane is one of the most commonly used inhalation
anesthetics. However, the effects of desflurane on AD neuropathogenesis have
not been previously determined. Here, we set out to assess the effects of
desflurane and hypoxia on caspase activation, amyloid precursor protein (APP)
processing, and amyloid β-protein (Aβ) generation in H4 human
neuroglioma cells (H4 naïve cells) as well as those overexpressing APP
(H4-APP cells). Neither 12% desflurane nor hypoxia (18% O2) alone
affected caspase-3 activation, APP processing, and Aβ generation.
However, treatment with a combination of 12% desflurane and hypoxia (18%
O2) (desflurane/hypoxia) for 6 h induced caspase-3 activation,
altered APP processing, and increased Aβ generation in H4-APP cells.
Desflurane/hypoxia also increased levels of β-site APP-cleaving enzyme in
H4-APP cells. In addition, desflurane/hypoxia-induced Aβ generation could
be reduced by the broad caspase inhibitor benzyloxycarbonyl-VAD. Finally, the
Aβ aggregation inhibitor clioquinol and γ-secretase inhibitor
L-685,458 attenuated caspase-3 activation induced by desflurane/hypoxia. In
summary, desflurane can induce Aβ production and caspase activation, but
only in the presence of hypoxia. Pending in vivo confirmation, these
data may have profound implications for anesthesia care in elderly patients,
and especially those with AD.An estimated 200 million patients worldwide undergo surgery each year.
Several reports have suggested that anesthesia and surgery may facilitate
development of Alzheimer disease
(AD)4
(1–3).
A recent study also reported that patients having coronary artery bypass graft
surgery under general anesthesia are at increased risk for AD as compared with
those having percutaneous transluminal coronary angioplasty under local
anesthesia (4).Genetic evidence, confirmed by neuropathological and biochemical findings,
indicates that excessive production and/or accumulation of amyloid
β-protein (Aβ) play a fundamental role in the pathology of AD
(reviewed in Refs. 5 and
6). Aβ is produced via
serial proteolysis of amyloid precursor protein (APP) by aspartyl protease
β-site APP-cleaving enzyme (BACE), or β-secretase,
andγ-secretase. BACE cleaves APP to generate a 99-residue
membrane-associated C terminus fragment (APP-C99). APP-C99 is further cleaved
by γ-secretase to release 4-kDa Aβ and β-amyloid precursor
protein intracellular domain
(7–9).
Presenilin and γ-secretase co-fractionate as a detergent-sensitive, high
molecular weight complex (10)
that includes at least three other proteins, nicastrin/APH-2, APH-1, and
PEN-2, all of which are necessary and sufficient for γ-secretase
activity
(11–13).
Increasing evidence indicates that apoptosis is associated with a variety of
neurodegenerative disorders, including AD (Refs.
14–17;
reviewed in Ref. 18). Aβ
has been shown to cause caspase activation and apoptosis, which can in turn
potentiate Aβ generation
(16,
19–28).
Finally, fibrillar aggregates of Aβ and oligomeric species of Aβ are
more neurotoxic
(29–37).Perioperative factors, including hypoxia
(38–42),
hypocapnia (43), and
anesthetics
(44–47),
have been reported to potentially contribute to AD neuropathogenesis. These
perioperative factors may also cause post-operative cognitive dysfunction, a
dementia associated with surgery and anesthesia, by triggering AD
neuropathogenesis.Isoflurane, sevoflurane, and desflurane are the most commonly used
inhalation anesthetics. It has been reported that isoflurane enhances the
oligomerization and cytotoxicity of Aβ
(44) and induces apoptosis
(48–51).
Our recent studies have shown that a clinically relevant concentration of
isoflurane can lead to caspase-3 activation, decrease cell viability, alter
APP processing, and increase Aβ generation in human H4 neuroglioma cells
overexpressing human APP
(45–47).
Loop et al. (49)
reported that isoflurane and sevoflurane, but not desflurane, can induce
caspase activation and apoptosis in human T lymphocytes. However, effects of
desflurane and desflurane plus other perioperative risk factors, e.g.
hypoxia, on APP processing and Aβ generation have not been assessed.In the present study, we set out to determine effects of desflurane,
hypoxia, and the combination of the two (desflurane/hypoxia) on caspase-3
activation, APP processing, and Aβ generation in H4 human neuroglioma
cells (H4 naïve cells) and H4 naïve cells stably transfected to
express full-length (FL) APP (H4-APP cells). We also investigated whether the
caspase inhibitor, Z-VAD, the γ-secretase inhibitor L-685,458, and the
Aβ aggregation inhibitor clioquinol could attenuate
desflurane/hypoxia-induced caspase-3 activation and Aβ generation. 相似文献
9.
Jacamo R Sinnett-Smith J Rey O Waldron RT Rozengurt E 《The Journal of biological chemistry》2008,283(19):12877-12887
Protein kinase D (PKD) is a serine/threonine protein kinase rapidly
activated by G protein-coupled receptor (GPCR) agonists via a protein kinase C
(PKC)-dependent pathway. Recently, PKD has been implicated in the regulation
of long term cellular activities, but little is known about the mechanism(s)
of sustained PKD activation. Here, we show that cell treatment with the
preferential PKC inhibitors GF 109203X or Gö 6983 blocked rapid
(1–5-min) PKD activation induced by bombesin stimulation, but this
inhibition was greatly diminished at later times of bombesin stimulation
(e.g. 45 min). These results imply that GPCR-induced PKD activation
is mediated by early PKC-dependent and late PKC-independent mechanisms.
Western blot analysis with site-specific antibodies that detect the
phosphorylated state of the activation loop residues Ser744 and
Ser748 revealed striking PKC-independent phosphorylation of
Ser748 as well as Ser744 phosphorylation that remained
predominantly but not completely PKC-dependent at later times of bombesin or
vasopressin stimulation (20–90 min). To determine the mechanisms
involved, we examined activation loop phosphorylation in a set of PKD mutants,
including kinase-deficient, constitutively activated, and PKD forms in which
the activation loop residues were substituted for alanine. Our results show
that PKC-dependent phosphorylation of the activation loop Ser744
and Ser748 is the primary mechanism involved in early phase PKD
activation, whereas PKD autophosphorylation on Ser748 is a major
mechanism contributing to the late phase of PKD activation occurring in cells
stimulated by GPCR agonists. The present studies identify a novel mechanism
induced by GPCR activation that leads to late, PKC-independent PKD
activation.A rapid increase in the synthesis of lipid-derived second messengers with
subsequent activation of protein phosphorylation cascades has emerged as a
fundamental signal transduction mechanism triggered by multiple extracellular
stimuli, including hormones, neurotransmitters, chemokines, and growth factors
(1). Many of these agonists
bind to G protein-coupled receptors
(GPCRs),4 activate
heterotrimeric G proteins and stimulate isoforms of the phospholipase C
family, including β, γ, δ, and ε (reviewed in Refs.
1 and
2). Activated phospholipase Cs
catalyze the hydrolysis of phosphatidylinositol 4,5-bisphosphate to produce
the second messengers inositol 1,4,5-trisphosphate and diacylglycerol (DAG).
Inositol 1,4,5-trisphosphate mobilizes Ca2+ from intracellular
stores (3,
4) whereas DAG directly
activates the classic (α, β, and γ) and novel (δ,
ε, η, and θ) isoforms of PKC
(5–7).
Although it is increasingly recognized that each PKC isozyme has specific
functions in vivo
(5–8),
the mechanisms by which PKC-mediated signals are propagated to critical
downstream targets remain incompletely defined.PKD, also known initially as PKCμ
(9,
10), and two recently
identified serine protein kinases termed PKD2
(11) and PKCν/PKD3
(12,
13), which are similar in
overall structure and primary amino acid sequence to PKD
(14), constitute a new protein
kinase family within the Ca2+/calmodulin-dependent protein kinase
group (15) and separate from
the previously identified PKCs
(14). Salient features of PKD
structure include an N-terminal regulatory region containing a tandem repeat
of cysteine-rich zinc finger-like motifs (termed the cysteine-rich domain)
that confers high affinity binding to phorbol esters and DAG
(9,
16,
17), followed by a pleckstrin
homology (PH) domain that negatively regulates catalytic activity
(18,
19). The C-terminal region of
the PKDs contains its catalytic domain, which is distantly related to
Ca2+-regulated kinases.In unstimulated cells, PKD is in a state of low kinase catalytic activity
maintained by the N-terminal domain, which represses the catalytic activity of
the enzyme by autoinhibition. Consistent with this model, deletions or single
amino acid substitutions in the PH domain result in constitutive kinase
activity
(18–20).
Physiological activation of PKD within cells occurs via a
phosphorylation-dependent mechanism first identified in our laboratory
(21). In response to cellular
stimuli, PKD is converted from a low activity form into a persistently active
form that is retained during isolation from cells, as shown by in
vitro kinase assays performed in the absence of lipid co-activators
(21,
22). PKD activation has been
demonstrated in response to engagement of specific GPCRs either by regulatory
peptides
(23–30)
or lysophosphatidic acid (27,
31,
32); signaling through
Gq, G12, Gi, and Rho
(27,
31–34);
activation of receptor tyrosine kinases, such as the platelet-derived growth
factor receptor (23,
35,
36); cross-linking of B-cell
receptor and T-cell receptor in B and T lymphocytes, respectively
(37–40);
and oxidative stress
(41–44).Throughout these studies, multiple lines of evidence indicated that PKC
activity is necessary for rapid PKD activation within intact cells. For
example, rapid PKD activation was selectively and potently blocked by cell
treatment with preferential PKC inhibitors (e.g. GF 109203X or
Gö 6983) that do not directly inhibit PKD catalytic activity
(21,
22), implying that PKD
activation in intact cells is mediated, directly or indirectly, through PKCs.
In line with this conclusion, cotransfection of PKD with active mutant forms
of “novel” PKCs (PKCs δ, ε, η, and θ)
resulted in robust PKD activation in the absence of cell stimulation
(21,
44–46).
Many reports demonstrated the operation of a rapid PKC/PKD signaling cascade
in response to multiple GPCR agonists in a broad range of cell types,
including normal and cancer cells (reviewed in Ref.
14). Our previous studies
identified Ser744 and Ser748 in the PKD activation loop
(also referred as the activation segment or T-loop) as phosphorylation sites
critical for PKC-mediated PKD activation (reviewed in Ref.
14). Collectively, these
findings demonstrated the existence of rapidly activated PKC-PKD protein
kinase cascade(s) and raised the possibility that some PKC-dependent
biological responses involve PKD acting as a downstream effector.PKD has been reported recently to mediate several important cellular
activities and processes, including signal transduction
(30,
47–49),
chromatin modification (50),
Golgi organization and function
(51,
52), c-Jun function
(47,
53,
54), NFκB-mediated gene
expression (43,
55,
56), and cell survival,
migration, and differentiation and DNA synthesis and proliferation (reviewed
in Ref. 14). Thus, mounting
evidence indicates that PKD has a remarkable diversity of both its signal
generation and distribution and its potential for complex regulatory
interactions with multiple downstream pathways, leading to multiple responses,
including long term cellular events. Despite increasing recognition of its
importance, very little is known about the mechanism(s) of sustained PKD
activation as opposed to the well documented rapid, PKC-dependent PKD
activation.The results presented here demonstrate that prolonged GPCR-induced PKD
activation is mediated by sequential PKC-dependent and PKC-independent phases
of regulation. We report here, for the first time, that PKD
autophosphorylation on Ser748 is a major mechanism contributing to
the late phase of PKD activation occurring in cells stimulated by GPCR
agonists. The present studies expand previous models of PKD regulation by
identifying a novel mechanism induced by GPCR activation that leads to late,
PKC-independent PKD activation. 相似文献
10.
11.
Kelly J. Inglis David Chereau Elizabeth F. Brigham San-San Chiou Susanne Sch?bel Normand L. Frigon Mei Yu Russell J. Caccavello Seth Nelson Ruth Motter Sarah Wright David Chian Pamela Santiago Ferdie Soriano Carla Ramos Kyle Powell Jason M. Goldstein Michael Babcock Ted Yednock Frederique Bard Guriqbal S. Basi Hing Sham Tamie J. Chilcote Lisa McConlogue Irene Griswold-Prenner John P. Anderson 《The Journal of biological chemistry》2009,284(5):2598-2602
Several neurological diseases, including Parkinson disease and dementia
with Lewy bodies, are characterized by the accumulation of α-synuclein
phosphorylated at Ser-129 (p-Ser-129). The kinase or kinases responsible for
this phosphorylation have been the subject of intense investigation. Here we
submit evidence that polo-like kinase 2 (PLK2, also known as serum-inducible
kinase or SNK) is a principle contributor to α-synuclein phosphorylation
at Ser-129 in neurons. PLK2 directly phosphorylates α-synuclein at
Ser-129 in an in vitro biochemical assay. Inhibitors of PLK kinases
inhibited α-synuclein phosphorylation both in primary cortical cell
cultures and in mouse brain in vivo. Finally, specific knockdown of
PLK2 expression by transduction with short hairpin RNA constructs or by
knock-out of the plk2 gene reduced p-Ser-129 levels. These results
indicate that PLK2 plays a critical role in α-synuclein phosphorylation
in central nervous system.The importance of α-synuclein to the pathogenesis of Parkinson
disease (PD)4 and the
related disorder, dementia with Lewy bodies (DLB), is suggested by its
association with Lewy bodies and Lewy neurites, the inclusions that
characterize these diseases
(1–3),
and demonstrated by the existence of mutations that cause syndromes mimicking
sporadic PD and DLB
(4–6).
Furthermore, three separate mutations cause early onset forms of PD and DLB.
It is particularly telling that duplications or triplications of the gene
(7–9),
which increase levels of α-synuclein with no alteration in sequence,
also cause PD or DLB.α-Synuclein has been reported to be phosphorylated on serine
residues, at Ser-87 and Ser-129
(10), although to date only
the Ser-129 phosphorylation has been identified in the central nervous system
(11,
12). Phosphorylation at
tyrosine residues has been observed by some investigators
(13,
14) but not by others
(10–12).
Phosphorylation at Ser-129 (p-Ser-129) is of particular interest because the
majority of synuclein in Lewy bodies contains this modification
(15). In addition, p-Ser-129
was found to be the most extensive and consistent modification in a survey of
synuclein in Lewy bodies (11).
Results have been mixed from studies investigating the function of
phosphorylation using S129A and S129D mutations to respectively block and
mimic the modification. Although the phosphorylation mimic was associated with
pathology in studies in Drosophila
(16) and in transgenic mouse
models (17,
18), studies using
adeno-associated virus vectors to overexpress α-synuclein in rat
substantia nigra found an exacerbation of pathology with the S129A mutation,
whereas the S129D mutation was benign, if not protective
(19). Interpretation of these
studies is complicated by a recent study showing that the S129D and S129A
mutations themselves have effects on the aggregation properties of
α-synuclein independent of their effects on phosphorylation, with the
S129A mutation stimulating fibril formation
(20). Clearly, determination
of the role of p-Ser-129 phosphorylation would be helped by identification of
the responsible kinase. In addition, identification will provide a
pathologically relevant way to increase phosphorylation in a cell or animal
model.Several kinases have been proposed to phosphorylate α-synuclein,
including casein kinases 1 and 2
(10,
12,
21) and members of the
G-protein-coupled receptor kinase family
(22). In this report, we offer
evidence that a member of the polo-like kinase (PLK) family, PLK2 (or
serum-inducible kinase, SNK), functions as an α-synuclein kinase. The
ability of PLK2 to directly phosphorylate α-synuclein at Ser-129 is
established by overexpression in cell culture and by in vitro
reaction with the purified kinase. We show that PLK2 phosphorylates
α-synuclein in cells, including primary neuronal cultures, using a
series of kinase inhibitors as well as inhibition of expression with RNA
interference. In addition, inhibitor and knock-out studies in mouse brain
support a role for PLK2 as an α-synuclein kinase in vivo. 相似文献
12.
13.
14.
Ellen J. Tisdale Fouad Azizi Cristina R. Artalejo 《The Journal of biological chemistry》2009,284(9):5876-5884
Rab2 requires glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and atypical
protein kinase Cι (aPKCι) for retrograde vesicle formation from
vesicular tubular clusters that sort secretory cargo from recycling proteins
returned to the endoplasmic reticulum. However, the precise role of GAPDH and
aPKCι in the early secretory pathway is unclear. GAPDH was the first
glycolytic enzyme reported to co-purify with microtubules (MTs). Similarly,
aPKC associates directly with MTs. To learn whether Rab2 also binds directly
to MTs, a MT binding assay was performed. Purified Rab2 was found in a
MT-enriched pellet only when both GAPDH and aPKCι were present, and
Rab2-MT binding could be prevented by a recombinant fragment made to the Rab2
amino terminus (residues 2-70), which directly interacts with GAPDH and
aPKCι. Because GAPDH binds to the carboxyl terminus of α-tubulin,
we characterized the distribution of tyrosinated/detyrosinated α-tubulin
that is recruited by Rab2 in a quantitative membrane binding assay.
Rab2-treated membranes contained predominantly tyrosinated α-tubulin;
however, aPKCι was the limiting and essential factor.
Tyrosination/detyrosination influences MT motor protein binding; therefore, we
determined whether Rab2 stimulated kinesin or dynein membrane binding.
Although kinesin was not detected on membranes incubated with Rab2, dynein was
recruited in a dose-dependent manner, and binding was aPKCι-dependent.
These combined results suggest a mechanism by which Rab2 controls MT and motor
recruitment to vesicular tubular clusters.The small GTPase Rab2 is essential for membrane trafficking in the early
secretory pathway and associates with vesicular tubular
clusters
(VTCs)2 located
between the endoplasmic reticulum (ER) and the cis-Golgi compartment
(1,
2). VTCs are pleomorphic
structures that sort anterograde-directed cargo from recycling proteins and
trafficking machinery retrieved to the ER
(3-6).
Rab2 bound to a VTC microdomain stimulates recruitment of soluble factors that
results in the release of vesicles containing the recycling protein p53/p58
(7). In that regard, we have
previously reported that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
atypical PKC ι (aPKCι) are Rab2 effectors that interact directly
with the Rab2 amino terminus and with each other
(8,
9). Their interaction requires
Src-dependent tyrosine phosphorylation of GAPDH and aPKCι
(10). Moreover, GAPDH is a
substrate for aPKCι (11).
GAPDH catalytic activity is not required for ER to Golgi transport indicating
that GAPDH provides a specific function essential for membrane trafficking
from VTCs independent of glycolytic function
(9). Indeed, phospho-GAPDH
influences MT dynamics in the early secretory pathway
(11).GAPDH was the first glycolytic enzyme reported to co-purify with
microtubules (MTs) (12) and
subsequently was shown to interact with the carboxyl terminus of
α-tubulin (13). The
binding of GAPDH to MTs promotes formation of cross-linked parallel MT arrays
or bundles (14,
15). GAPDH has also been
reported to possess membrane fusogenic activity, which is inhibited by tubulin
(16). Similarly, aPKC
associates directly with tubulin and promotes MT stability and MT remodeling
at specific intracellular sites
(17-21).
It may not be coincidental that these two Rab2 effectors influence MT dynamics
because recent studies indicate that the cytoskeleton plays a central role in
the organization and operation of the secretory pathway
(22).MTs are dynamic structures that grow or shrink by the addition or loss of
α- and β-tubulin heterodimers from the ends of protofilaments
(23). Their assembly and
stability is regulated by a variety of proteins traditionally referred to as
microtubule-associated proteins (MAPs). In addition to the multiple
α/β isoforms that are present in eukaryotes, MTs undergo an
assortment of post-translational modifications, including acetylation,
glycylation, glutamylation, phosphorylation, palmitoylation, and
detyrosination, which further contribute to their biochemical heterogeneity
(24,
25). It has been proposed that
these tubulin modifications regulate intracellular events by facilitating
interaction with MAPs and with other specific effector proteins
(24). For example, the
reversible addition of tyrosine to the carboxyl terminus of α-tubulin
regulates MT interaction with plus-end tracking proteins (+TIPs) containing
the cytoskeleton-associated protein glycine-rich (CAP-Gly) motif and with
dynein-dynactin
(27-29).
Additionally, MT motility and cargo transport rely on the cooperation of the
motor proteins kinesin and dynein
(30). Kinesin is a plus-end
directed MT motor, whereas cytoplasmic dynein is a minus-end MT-based motor,
and therefore the motors transport vesicular cargo toward the opposite end of
a MT track (31).Although MT assembly does not appear to be directly regulated by small
GTPases, Rab proteins provide a molecular link for vesicle movement along MTs
to the appropriate target (22,
32-34).
In this study, the potential interaction of Rab2 with MTs and motor proteins
was characterized. We found that Rab2 does not bind directly to preassembled
MTs but does associate when both GAPDH and aPKCι are present and bound to
MTs. Moreover, the MTs predominantly contained tyrosinated α-tubulin
(Tyr-tubulin) suggesting that a dynamic pool of MTs that differentially binds
MAPs/effector proteins/motors associates with VTCs in response to Rab2. To
that end, we determined that Rab2-promoted dynein/dynactin binding to
membranes and that the recruitment required aPKCι. 相似文献
15.
16.
17.
18.
19.
Haipeng Cheng Kulandaivelu S. Vetrivel Renaldo C. Drisdel Xavier Meckler Ping Gong Jae Yoon Leem Tong Li Meghan Carter Ying Chen Phuong Nguyen Takeshi Iwatsubo Taisuke Tomita Philip C. Wong William N. Green Maria Z. Kounnas Gopal Thinakaran 《The Journal of biological chemistry》2009,284(3):1373-1384
Proteolytic processing of amyloid precursor protein (APP) by β- and
γ-secretases generates β-amyloid (Aβ) peptides, which
accumulate in the brains of individuals affected by Alzheimer disease.
Detergent-resistant membrane microdomains (DRM) rich in cholesterol and
sphingolipid, termed lipid rafts, have been implicated in Aβ production.
Previously, we and others reported that the four integral subunits of the
γ-secretase associate with DRM. In this study we investigated the
mechanisms underlying DRM association of γ-secretase subunits. We report
that in cultured cells and in brain the γ-secretase subunits nicastrin
and APH-1 undergo S-palmitoylation, the post-translational covalent
attachment of the long chain fatty acid palmitate common in lipid
raft-associated proteins. By mutagenesis we show that nicastrin is
S-palmitoylated at Cys689, and APH-1 is
S-palmitoylated at Cys182 and Cys245.
S-Palmitoylation-defective nicastrin and APH-1 form stable
γ-secretase complexes when expressed in knock-out fibroblasts lacking
wild type subunits, suggesting that S-palmitoylation is not essential
for γ-secretase assembly. Nevertheless, fractionation studies show that
S-palmitoylation contributes to DRM association of nicastrin and
APH-1. Moreover, pulse-chase analyses reveal that S-palmitoylation is
important for nascent polypeptide stability of both proteins. Co-expression of
S-palmitoylation-deficient nicastrin and APH-1 in cultured cells
neither affects Aβ40, Aβ42, and AICD production, nor intramembrane
processing of Notch and N-cadherin. Our findings suggest that
S-palmitoylation plays a role in stability and raft localization of
nicastrin and APH-1, but does not directly modulate γ-secretase
processing of APP and other substrates.Alzheimer disease is the most common among neurodegenerative diseases that
cause dementia. This debilitating disorder is pathologically characterized by
the cerebral deposition of 39–42 amino acid peptides termed Aβ,
which are generated by proteolytic processing of amyloid precursor protein
(APP)2 by β- and
γ-secretases (1,
2). The β-site APP
cleavage enzyme 1 cleaves full-length APP within its luminal domain to
generate a secreted ectodomain leaving behind a C-terminal fragment
(β-CTF). γ-Secretase cleaves β-CTF within the transmembrane
domain to release Aβ and APP intracellular
C-terminal domain (AICD). γ-Secretase is a
multiprotein complex, comprising at least four subunits: presenilins (PS1 and
PS2), nicastrin, APH-1, and PEN-2 for its activity
(3). PS1 is synthesized as a
42–43-kDa polypeptide and undergoes highly regulated endoproteolytic
processing within the large cytoplasmic loop domain connecting putative
transmembrane segments 6 and 7 to generate stable N-terminal (NTF) and
C-terminal fragments (CTF) by an uncharacterized proteolytic activity
(4). This endoproteolytic event
has been identified as the activation step in the process of PS1 maturation as
it assembles with other γ-secretase subunits
(3). Nicastrin is a heavily
glycosylated type I membrane protein with a large ectodomain that has been
proposed to function in substrate recognition and binding
(5), but this putative function
has not been confirmed by others
(6). APH-1 is a
seven-transmembrane protein encoded by two human or three rodent genes that
are alternatively spliced (7).
Although PS1 (or PS2), nicastrin, APH-1, and PEN-2 are sufficient for
γ-secretase processing of APP, a type I membrane protein, termed p23
(also referred toTMP21), was recently identified as a γ-secretase
component that modulates γ-secretase activity and regulates secretory
trafficking of APP (8,
9).A growing number of type I integral membrane proteins has been identified
as γ-secretase substrates within the last few years, including Notch1
homologues, Notch ligands, Delta and Jagged, cell adhesion receptors N- and
E-cadherins, low density lipoprotein receptor-related protein, ErbB-4, netrin
receptor DCC, and others (10).
Mounting evidence suggests that APP processing occurs within cholesterol- and
sphingolipid-enriched lipid rafts, which are biochemically defined as
detergentresistant membrane microdomains (DRM)
(11,
12). Previously we reported
that each of the γ-secretase subunits localizes in lipid rafts in
post-Golgi and endosome membranes enriched in syntaxin 6
(13). Moreover, loss of
γ-secretase activity by gene deletion or exposure to γ-secretase
inhibitors results in the accumulation of APP CTFs in lipid rafts indicating
that cleavage of APP CTFs likely occurs in raft microdomains
(14). In contrast, CTFs
derived from Notch1, Jagged2, N-cadherin, and DCC are processed by
γ-secretase in non-raft membranes
(14). The mechanisms
underlying association of γ-secretase subunits with lipid rafts need
further clarification to elucidate spatial segregation of amyloidogenic
processing of APP in membrane microdomains.Post-translational S-palmitoylation is increasingly recognized as
a potential mechanism for regulating raft association, stability,
intracellular trafficking, and function of several cytosolic and transmembrane
proteins
(15–17).
S-palmitoylation refers to the addition of 16-carbon palmitoyl moiety
to certain cysteine residues through thioester linkage. Cysteines close to
transmembrane domains or membrane-associated domains in non-integral membrane
proteins are preferred S-palmitoylation sites, although no conserved
motif has been identified
(18). Palmitoylation modifies
numerous neuronal proteins, including postsynaptic density protein PSD-95
(19),
a-amino-3-hydroxyl-5-methyl-4-isoxazole propionic acid receptors
(20), nicotinic α7
receptors (21), neuronal
t-SNAREs SNAP-25, synaptobrevin 2 and synaptogagmin
(22,
23), neuronal
growth-associated protein GAP-43
(24), protein kinase CLICK-III
(CL3)/CaMKIγ (25),
β-secretase (26), and
Huntingtin (27). Although
palmitoylation can occur in vitro without the involvement of an
enzyme, a family of palmitoyltransferases that specifically catalyze
S-palmitoylation has been identified
(28,
29).In this study, we have identified S-palmitoylation of
γ-secretase subunits nicastrin and APH-1, and characterized its role on
DRM association, protein stability, and γ-secretase enzyme activities.
We show that nicastrin is S-palmitoylated at Cys689, and
APH-1 at Cys182 and Cys245. Mutagenesis of
palmitoylation sites results in increased degradation of nascent nicastrin and
APH-1 polypeptides and reduced association with DRM. Nevertheless, in cultured
cells overexpression of S-palmitoylation-deficient nicastrin and
APH-1 does not modulate γ-secretase processing of APP or other
substrates. 相似文献
20.
Matthias Gralle Michelle Gralle Botelho Fred S. Wouters 《The Journal of biological chemistry》2009,284(22):15016-15025
The amyloid precursor protein (APP) is implied both in cell growth and
differentiation and in neurodegenerative processes in Alzheimer disease.
Regulated proteolysis of APP generates biologically active fragments such as
the neuroprotective secreted ectodomain sAPPα and the neurotoxic
β-amyloid peptide. Furthermore, it has been suggested that the intact
transmembrane APP plays a signaling role, which might be important for both
normal synaptic plasticity and neuronal dysfunction in dementia. To understand
APP signaling, we tracked single molecules of APP using quantum dots and
quantitated APP homodimerization using fluorescence lifetime imaging
microscopy for the detection of Förster resonance energy transfer in
living neuroblastoma cells. Using selective labeling with synthetic
fluorophores, we show that the dimerization of APP is considerably higher at
the plasma membrane than in intracellular membranes. Heparan sulfate
significantly contributes to the almost complete dimerization of APP at the
plasma membrane. Importantly, this technique for the first time structurally
defines the initiation of APP signaling by binding of a relevant physiological
extracellular ligand; our results indicate APP as receptor for neuroprotective
sAPPα, as sAPPα binding disrupts APP dimers, and this disruption
of APP dimers by sAPPα is necessary for the protection of neuroblastoma
cells against starvation-induced cell death. Only cells expressing reversibly
dimerized wild-type, but not covalently dimerized mutant APP are protected by
sAPPα. These findings suggest a potentially beneficial effect of
increasing sAPPα production or disrupting APP dimers for neuronal
survival.The amyloid precursor protein
(APP)4 is known both
for its important role in the development and plasticity of the nervous system
(1–6)
and for its involvement in Alzheimer disease (AD)
(7,
8). Despite intensive research
efforts, the initial events that lead to the prevalent sporadic, i.e.
non-familial, forms of AD are still unclear. Furthermore, although a higher
gene dose of APP (9) or the
presence of pathological APP mutations is sufficient to induce familial AD
(for review, see Ref. 10), the
exact pathological mechanism that is triggered by APP is still under
debate.Some fragments of APP, such as the β-amyloid peptide (Aβ), are
thought to contribute to synaptic dysfunction and neurotoxicity
(11,
12). On the other hand, the
α-secretase-derived extracellular fragment of APP (sAPPα), which
is present at lower levels in AD patients than in controls
(13), has been shown to be
beneficial for memory function, to possess neuroprotective properties, and to
counteract the effects of Aβ
(14–18).Signaling by transmembrane APP may directly contribute to neurodegeneration
in AD
(19–24);
however, the signal transduction pathway for transmembrane APP remains
unknown, although several potential regulatory proteins, glycosaminoglycans,
and metal ions are known to bind with high affinity to APP and sAPPα
(25,
26). The most common form of
signal transduction for single-pass transmembrane proteins is the
ligand-induced perturbation of a monomer/dimer equilibrium. Indeed, the
dimerization of transmembrane APP has been implied several times in the past.
Several studies have investigated the effects of presumed dimer-breaking
perturbations on biological read-outs, such as the production of Aβ
(27,
28), but without directly
measuring the APP aggregation state, or have investigated the aggregation
state of APP subdomains, often reconstituted in cell-free systems
(27–32).
Dimerization interfaces in both the extracellular and the transmembrane domain
have been suggested.In the studies investigating the aggregation state of full-length APP, most
of the employed methods, such as chemical cross-linking and
co-immunoprecipitation, do not lend themselves readily to a rigorous
quantitative analysis of the abundance of potentially instable dimers
(31,
33), whereas in other cases
the use of chimeras may have influenced the dimerization potential or
precluded the search for a natural stimulus
(23,
34). The only previously
reported direct observation of APP dimerization by Förster resonance
energy transfer (FRET) microscopy uses an assay in which the FRET efficiency
varies with the level of overexpression
(35). Therefore, a
concentration-dependent FRET component due to nonspecific stochastic
encounters cannot be excluded in this study.Most importantly, as none of the published procedures permitted the
selective detection of APP dimers on the surface of live cells, where they
would encounter ligands, they could not differentiate between subpopulations
of APP. This may be one reason why no natural ligand of APP has ever been
shown to signal via modulation of its monomer/dimer equilibrium.Another elusive goal is the identity of the receptor for neuroprotective
sAPPα
(36–39).
The ligand-dependent dimerization of sAPPα in solution
(40) and its origination from
transmembrane APP suggest that APP might serve as receptor for sAPPα,
but this binding has never been experimentally shown. 相似文献